TNF and histoplasmosis: While multiple types of immunosuppressive medications may be associated with an increased risk of histoplasmosis, patients receiving TNF-α inhibitors (infliximab, etanercept, adalimumab, certolizumab, golimumab) are at the highest risk of intracellular infections, including histoplasmosis.